Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of JAB-21822 alone and with cetuximab in KRAS G12C-mutant advanced solid tumors
MOH_2022-01-12_010536Phase 2Active, not recruiting
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glecirasib and cetuximab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (5 arms), sponsored by Jacobio Pharmaceuticals. Primary endpoints: Safety and tolerability and Pharmacokinetics. Started Nov 2021; status: active, not recruiting.
02
Drugs
glecirasibcetuximab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2022-01-12_010536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-12_010536.